Saturday 17 October 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024. In the quarter to June 2026, revenue grew 64.4%, EPS grew 817.3%, free cash flow grew 400.7% and total debt rose 74.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
98.06
4.67
−4.55%
Follow BLLN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 80.51 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 138.70 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 620 | 713 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.25 | 0.43 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 72 | 153 | 305 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 24.13 | 53.03 | 68.32 | |||||
| EBT | — | — | — | — | — | — | — | (83) | (42) | 8 | |||||
| EBT margin, % | — | — | — | — | — | — | — | (115.26) | (27.23) | 2.54 | |||||
| Net income | — | — | — | — | — | — | — | (83) | (42) | 7 | |||||
| Depreciation | — | — | — | — | — | — | — | 7 | 12 | 12 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 7.33 | 15.14 | 19.22 | ||||
| Earnings | — | — | — | — | — | — | — | (8.45) | (4.12) | 0.18 | |||||
| Cash flow | — | — | — | — | — | — | — | (5.49) | (4.10) | 1.55 | |||||
| Capex | — | — | — | — | — | — | — | (0.63) | (0.54) | (0.56) | |||||
| Free cash flow | — | — | — | — | — | — | — | (6.12) | (4.64) | 0.99 | |||||
| Book value | — | — | — | — | — | — | — | 0.00 | (24.97) | 30.24 | |||||
| Shares, m | — | — | — | — | — | — | — | 10 | 10 | 16 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 1,320.00 | ||||
| P/S | — | — | — | — | — | — | — | 4.59 | 4.59 | 4.26 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 2.71 | |||||
| EV/Sales | — | — | — | — | — | — | — | 4.03 | 4.03 | 2.82 | |||||
| EV/FCF | — | — | — | — | — | — | — | (246.78) | (246.78) | 54.78 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (54) | (41) | 25 | ||||
| Capex | — | — | — | — | — | — | — | (6) | (5) | (9) | |||||
| Free cash flow | — | — | — | — | — | — | — | (60) | (47) | 16 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 199 | 513 | ||||
| Total debt | — | — | — | — | — | — | — | — | 52 | 58 | |||||
| Net debt | — | — | — | — | — | — | — | — | (139) | (438) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (252) | 480 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (27.52) | 0.62 | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 24.01 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 0.00 | 2.56 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
BillionToOne, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| QGEN QIAGEN N.V. | $9.5B | 23.6× | 17.5× | +0.28% (above 0%: growing) | +7.94% (above 0%: growing) | +30.45% (above 0%: growing) | 63.62% | 24.75% | Compare |
| TWST Twist Bioscience Corporation | $9.5B | — (loss-making) | — (loss-making) | +23.24% (above 0%: growing) | n/m | −7.23% (below 0%: shrinking) | 52.76% | (30.65%) | Compare |
| GRAL GRAIL, Inc. | $6.1B | — (loss-making) | — (loss-making) | +25.72% (above 0%: growing) | n/m | −4.95% (below 0%: shrinking) | (28.12%) | (388.89%) | Compare |
| RDNT RadNet, Inc. | $5.5B | — (loss-making) | 279× | +24.99% (above 0%: growing) | −47.37% (below 0%: shrinking) | −43.22% (below 0%: shrinking) | 14.14% | 6.34% | Compare |
| SHC Sotera Health Company | $5.2B | 31.4× | 23.7× | +9.18% (above 0%: growing) | +533.33% (above 0%: growing) | +60.56% (above 0%: growing) | 55.38% | 33.23% | Compare |
| BLLN BillionToOne, Inc. | $4.9B | 95.0× | 99.4× | +64.40% (above 0%: growing) | n/m | +400.65% (above 0%: growing) | 70.45% | 5.03% | |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | — (loss-making) | — (loss-making) | +21.53% (above 0%: growing) | n/m | +42.04% (above 0%: growing) | 71.82% | (22.04%) | Compare |
| VCYT Veracyte, Inc. | $3.6B | 29.9× | 45.1× | +15.49% (above 0%: growing) | n/m | +32.95% (above 0%: growing) | 72.21% | 15.29% | Compare |
| CDNA CareDx, Inc. | $3.5B | 29.7× | 2,967× | +52.23% (above 0%: growing) | n/m | +223.42% (above 0%: growing) | 73.50% | 85.81% | Compare |
| Median of peers | $5.4B | 29.8× | 45.1× | +22.39% | +7.94% | +31.70% | 59.50% | 10.82% |
BillionToOne, Inc. (BLLN) key facts
- Strength: BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- BillionToOne, Inc. (BLLN) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BLLN traded at $98.06, a market capitalization of $4.9 billion.
- Return on equity was 2.56% and debt-to-equity 0.17.
- Its Altman Z-score is 6.04 (safe zone) for fiscal 2025.
BillionToOne, Inc. (BLLN) Latest News
No news at this impact. Lower the threshold for more.